ClinicalTrials.gg
CompletedNCT01020448TriptocareUpdated Jan 30, 2019Results posted

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

A Phase 3 interventional study of Triptorelin (Decapeptyl®) in Prostate Cancer, sponsored by Ipsen. Completed at 59 sites in 10 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-30.

Sponsored by Ipsen · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
339
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Enrollment
5th of 28
339 · median 120
Started
2009
the only one that year
Phase 3
12 of 28
2 open now
Registered
7th of 28
by date
Lead sponsor
9 of 28
Ipsen

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2009, is one of 12 in phase 3, and was the 7th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced stages of prostate cancer. Their characteristics, according to risk factors such as PSA and Gleason score will be determined at baseline and 1, 3 and 6 month post-treatment.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Locally advanced or metastatic Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A confirmed, locally advanced or prostate cancer, and naïve to androgen deprivation therapy, and a candidate for hormonal treatment.
  • An estimated survival time of at least twelve months according to the investigator's assessment.
  • A performance status score ≤ 2 according to the World Health Organisation (WHO) criteria.

Exclusion criteria

Exclusion Criteria:

  • Previous surgical castration.
  • Previous or has planned curative prostate cancer therapy (radiation/surgery)
  • Previous hormone therapy (GnRH analogues, estrogens or anti-androgens)
  • Patients with risk of a serious complication in the case of tumour flare (vertebral threatening spinal cord compression or significant obstructive uropathy)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
339 participants (actual)

Study arms

  • Experimental
    Triptorelin (Decapeptyl®) 22.5 mg

    Drug: Triptorelin (Decapeptyl®)

Interventions

  • One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.

06

What researchers measure

Primary outcomes

  1. PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA

    PCA-3 score = (mRNA PCA3/mRNA PSA)x1000 * Non-assessable = Associated PSA mRNA \<7500 copies/mL * ≤BLQ = PCA-3 mRNA is below the concentration of the calibrator and associated PSA mRNA \>7500 copies/mL * \<35 = PCA-3 mRNA above BLQ and less than 35 * ≥35 = PCA-3 mRNA greater or equal to 35

    Time frame: At month 6 post-treatment

Secondary outcomes

  1. PCA3 Score Expressed as a Ratio of PCA3 mRNA Over PSA mRNA

    PCA-3 score = (mRNA PCA3/mRNA PSA)x1000 * Non-assessable = Associated PSA mRNA \<7500 copies/mL * ≤BLQ = PCA-3 mRNA is below the concentration of the calibrator and associated PSA mRNA \>7500 copies/mL * \<35 = PCA-3 mRNA above BLQ and less than 35 * ≥35 = PCA-3 mRNA greater or equal to 35

    Time frame: At month 1 and 3 post-treatment

  2. TMPRSS2-ERG Score (Expressed as a Ratio of T2-ERG mRNA Over PSA mRNA)

    TMPRSS2-ERG = (TMPRSS2-ERG mRNA / PSA mRNA) x 100000 A TMPRSS2-ERG score \<35 was described as 'negative' and a TMPRSS2-ERG score ≥35 as 'positive.'

    Time frame: At baseline, month 1, 3 and 6 post-treatment

  3. Proportion of Patients Medically Castrated (i.e. With Serum Testosterone Levels of <50 ng/dL)

    Time frame: At month 1, 3 and 6 post-treatment

  4. PSA Level

    Time frame: At baseline, month 1, 3 and 6 post-treatment

  5. Safety, Assessed Through the Collection of Adverse Events (AEs)

    Time frame: For the duration of the study (up to month 6)

07

Results

Posted Jul 15, 2015

Participant flow

Study Initiation Date: 30-Nov-2009. Subjects screened were 339 and screen failures were 13.

Pre-assignment
Participant flow — Pre-assignment
MilestoneTriptorelin (Decapeptyl®) 22.5 mg
Started339
Completed326
Not completed13
Withdrew: Adverse event6
Withdrew: Withdrawal by subject5
Withdrew: Does not meet entry criteria2
Treatment
Participant flow — Treatment
MilestoneTriptorelin (Decapeptyl®) 22.5 mg
Started325
Completed299
Not completed26
Withdrew: Adverse event11
Withdrew: Consent withdrawn3
Withdrew: Disease progression2
Withdrew: Lack of efficacy8
Withdrew: Lost to follow-up2

Outcome measures

PrimaryPCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA

PCA-3 score = (mRNA PCA3/mRNA PSA)x1000 * Non-assessable = Associated PSA mRNA \<7500 copies/mL * ≤BLQ = PCA-3 mRNA is below the concentration of the calibrator and associated PSA mRNA \>7500 copies/mL * \<35 = PCA-3 mRNA above BLQ and less than 35 * ≥35 = PCA-3 mRNA greater or equal to 35

Time frame:
At month 6 post-treatment
Reported as:
Number · participants
PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA
participantsTriptorelin (Decapeptyl®) 22.5 mg
Non-assessable232
≤BLQ27
<3510
≥3524
Missing - No sample analysis done5
SecondaryPCA3 Score Expressed as a Ratio of PCA3 mRNA Over PSA mRNA

PCA-3 score = (mRNA PCA3/mRNA PSA)x1000 * Non-assessable = Associated PSA mRNA \<7500 copies/mL * ≤BLQ = PCA-3 mRNA is below the concentration of the calibrator and associated PSA mRNA \>7500 copies/mL * \<35 = PCA-3 mRNA above BLQ and less than 35 * ≥35 = PCA-3 mRNA greater or equal to 35

Time frame:
At month 1 and 3 post-treatment
Reported as:
Number · participants
PCA3 Score Expressed as a Ratio of PCA3 mRNA Over PSA mRNA
participantsTriptorelin (Decapeptyl®) 22.5 mg
Month 1: Non-assessable (N=322)109
Month 1: ≤BLQ (N=322)40
Month 1: <35 (N=322)80
Month 1: ≥35 (N=322)91
Month 1: Missing - No sample analysis done (N=322)2
Month 3: Non-assessable (N=313)215
Month 3: ≤BLQ (N=313)31
Month 3: <35 (N=313)34
Month 3: ≥35 (N=313)31
Month 3: Missing - No sample analysis done (N=313)2
SecondaryTMPRSS2-ERG Score (Expressed as a Ratio of T2-ERG mRNA Over PSA mRNA)

TMPRSS2-ERG = (TMPRSS2-ERG mRNA / PSA mRNA) x 100000 A TMPRSS2-ERG score \<35 was described as 'negative' and a TMPRSS2-ERG score ≥35 as 'positive.'

Time frame:
At baseline, month 1, 3 and 6 post-treatment
Reported as:
Number · participants
TMPRSS2-ERG Score (Expressed as a Ratio of T2-ERG mRNA Over PSA mRNA)
participantsTriptorelin (Decapeptyl®) 22.5 mg
Baseline: Non-assessable (N=322)33
Baseline: <35 negative (N=322)140
Baseline: ≥35 positive (N=322)149
Month 1: Non-assessable (N=322)117
Month 1: <35 negative (N=322)97
Month 1: ≥35 positive (N=322)106
Month 1: Missing - No sample analysis done (N=322)2
Month 3: Non-assessable (N=313)213
Month 3: <35 negative (N=313)45
Month 3: ≥35 positive (N=313)53
Month 3: Missing - No sample analysis done (N=313)2
Month 6: Non-assessable (N=298)241
Month 6: <35 negative (N=298)24
Month 6: ≥35 positive (N=298)27
Month 6: Missing - No sample analysis done (N=298)6
SecondaryProportion of Patients Medically Castrated (i.e. With Serum Testosterone Levels of <50 ng/dL)
Time frame:
At month 1, 3 and 6 post-treatment
Reported as:
Number · percentage of participants
Proportion of Patients Medically Castrated (i.e. With Serum Testosterone Levels of <50 ng/dL)
percentage of participantsTriptorelin (Decapeptyl®) 22.5 mg
Month 1 (N=322)94.7
Month 3 (N=313)95.2
Month 6 (N=298)90.9
SecondaryPSA Level
Time frame:
At baseline, month 1, 3 and 6 post-treatment
Reported as:
Median · μg/L
PSA Level
μg/LTriptorelin (Decapeptyl®) 22.5 mg
Baseline (N=321)45.4 (1 to 12239)
Month 1 (N=320)8.3 (0 to 581)
Month 3 (N=311)1.8 (0 to 969)
Month 6 (N=296)1.2 (0 to 1251)
SecondarySafety, Assessed Through the Collection of Adverse Events (AEs)
Time frame:
For the duration of the study (up to month 6)
Reported as:
Number · participants
Safety, Assessed Through the Collection of Adverse Events (AEs)
participantsTriptorelin (Decapeptyl®) 22.5 mg
Any Adverse Events (AEs)193
Any Treatment Emergent Adverse Events (TEAEs)190
TEAEs Leading to Withdrawal11
TEAEs Leading to Death11
Serious Adverse Events (SAEs)37

Adverse events

Collected over Up to month 6. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triptorelin (Decapeptyl®) 22.5 mg—37/325 (11.4%)89/325 (27.4%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventTriptorelin (Decapeptyl®) 22.5 mg
FallInjury, poisoning and procedural complications2/325
Heart failureCardiac disorders2/325
Renal failureRenal and urinary disorders2/325
Severe anemiaBlood and lymphatic system disorders2/325
Bone pain due to metastasisNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/325
Acute pneumoniaInfections and infestations2/325
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/325
Hip fractureInjury, poisoning and procedural complications1/325
Chronic heart failureCardiac disorders1/325
Perforated colonGastrointestinal disorders1/325
Most frequent other events
Most frequent other events
EventTriptorelin (Decapeptyl®) 22.5 mg
Hot flushVascular disorders89/325

Baseline characteristics

Age, Continuous
Age, Continuous(years)Triptorelin (Decapeptyl®) 22.5 mg
Mean72.6 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Triptorelin (Decapeptyl®) 22.5 mg
Female0
Male325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Triptorelin (Decapeptyl®) 22.5 mg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American7
White307
More than one race0
Unknown or Not Reported10
Height
Height(Cm)Triptorelin (Decapeptyl®) 22.5 mg
Mean172.3 ± 6.5
Weight
Weight(KG)Triptorelin (Decapeptyl®) 22.5 mg
Mean79.6 ± 13.4
BMI
BMI(kg/m²)Triptorelin (Decapeptyl®) 22.5 mg
Mean26.79 ± 4.23
PCA-3 Score
PCA-3 Score(participants)Triptorelin (Decapeptyl®) 22.5 mg
Non-assessable39
≤BLQ15
<3589
≥35179
Missing - No sample analysis done3
08

Study locations

59 sites
  • Hôpital Erasme
    Brussels, 1070, Belgium
  • UZ Brussels
    Brussels, 1090, Belgium
  • UCL Saint-Luc
    Brussels, 1200, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU de Liège
    Liège, 4000, Belgium
  • Fredericia Sygehus
    Fredericia, Denmark
  • Frederiksbergs Hospital
    Frederiksberg, 2000, Denmark
  • Herlev University Hospital
    Herlev, 2730, Denmark
  • Odense Universitets hospital
    Odense, 5000, Denmark
  • Clinique Rhône Durance
    Avignon, 84000, France
  • Hôpital Pellegrin
    Bordeaux, 33076, France
  • CHU Henri Mondor
    Créteil, 94010, France
  • CHU Michalon
    Grenoble, 38043, France
  • Chru Lille
    Lille, 59037, France
  • Hôpital Nord
    Marseille, 13915, France
  • Clinique Beau Soleil
    Montpellier, 34000, France
  • Private practice
    Nancy, 54100, France
  • CHU Nantes
    Nantes, 44093, France
  • CHU Pasteur
    Nice, 06002, France
  • Hôpital Val de Grâce
    Paris, 75005, France
  • Institut Mutualiste Monsouris
    Paris, 75014, France
  • Hôpital Henry Gabrielle
    Saint Genis Laval, 69230, France
  • Hôpital Foch
    Suresnes, 92150, France
  • CHU Toulouse
    Toulouse, 31059, France
  • IRCCS Fondazione S. Raffaele del Monte Tabor
    Milano, 20132, Italy
  • AOU San Luigi Gonzaga
    Torino, 10043, Italy
  • P.Stradins Clinical University Hospital
    Riga, LV 1002, Latvia
  • Center of Oncology
    Riga, LV1079, Latvia
  • Medical University Clinics
    Kaunas, LT-50009, Lithuania
  • University Hospital
    Klaipeda, Lithuania
  • University Oncological Institute
    Vilnius, LT-08660, Lithuania
  • Ziekenhuis Amstelland
    Amstelveen, Netherlands
  • Academisch Medisch Centrum
    Amsterdam, 1105 AZ, Netherlands
  • Diaconessenhuis
    Leiden, 2333ZA, Netherlands
  • Antonius Ziekenhuis
    Sneek, Netherlands
  • Medical Center
    Arad, Romania
  • Oncology Institute
    Bucharest, 72435, Romania
  • Sc E-Uro Srl
    Cluj Napoca, Romania
  • Oncomed
    Timisoara, Romania
  • Hospital Valle Hebrón
    Barcelona, 08035, Spain
  • Hospital Clinic
    Barcelona, 08036, Spain
  • Hospital de Basurto
    Bilbao, 48013, Spain
  • Hospital Juan Canalejo
    Coruña, 15006, Spain
  • Hospital General Universitario
    Madrid, 28007, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Infanta Sofía
    Madrid, 28702, Spain
  • Instituto de Oncología
    Valencia, 46009, Spain
  • Bristol Royal Infirmary
    Bristol, United Kingdom
  • Addenbrookes Hospital
    Cambridge, CB2 8RP, United Kingdom
  • University Hospital Wales
    Cardiff, CF14 4XW, United Kingdom
  • University Hospital Coventry
    Coventry, CV3 / CV2 2DX, United Kingdom
  • Derby City Hosptial
    Derby, DE22 3NE, United Kingdom
  • Royal Devon and Exeter Hospital
    Exeter, EX2 5DW, United Kingdom
  • Falkirk & District Royal Infirmary
    Falkirk, FK1 5QE, United Kingdom
  • Leicester General Hospital
    Leicester, LE5 4PW, United Kingdom
  • Freeman Hospital
    Newcastle upon Tyne, NE7 7DN, United Kingdom
  • Nottingham City Hospital
    Nottingham, NG5 1PB, United Kingdom
  • Lister Hospital
    Stevenage, SG1 4AB, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Nov 2011 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2009
First posted
Nov 25, 2009
Start
Nov 2009
Primary completionActual
Nov 2011
CompletionActual
Jun 2013
Results first posted
Jul 15, 2015
Last update
Jan 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01020448
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Nov 25, 2009
Start date
Nov 2009
Primary completion
Nov 2011
Completion
Jun 2013
Results posted
Jul 15, 2015
Last update
Jan 30, 2019

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion